Mediwound Ltd. · NASDAQ:MDWD
Mediwound — Investor Presentation (January 2025)
29 slides from Mediwound's investor presentation, Jan 8, 2025
Slide 1: Next-Generation Enzymatic Therapeutics for Non-Surgical Tissue Repair
January 2025 I Nasdaq: MDWD Next - Generation Enzymatic Therapeutics for Non - Surgical Tissue Repair
Slide 2: Cautionary Note Regarding Forward-Looking Statements
2 Cautionary Note Regarding Forward - Looking Statements This presentation contains “ forward - looking statements ” within the meaning of the Private Securities Litigation Reform Act and other securities laws, including but not limited to the statements related to the commercial potential of our pr
Slide 3: MediWound - Company Highlights
Validated enzymatic technology platform Vericel, Mölnlycke, Kaken, MiMedx , BARDA, EIC, DoD , PolyMedics , Mankind, Solventum S trategic g lobal collaborations Solid balance sheet with strong investor base 3 MediWound - Company Highlights 1 . Investigational drug 2 . Primary Research, Alira Health a
Slide 4: Core Platform - Enzymatic Technology
Proprietary IP protected manufacturing process 4 Core Platform - Enzymatic Technology Pineapple stem harvest Protein extraction Purification, enrichment, stabilization Healthy skin Damaged skin Complex mixture of enzymes Rapid removal of non - viable tissue without surgery Post application Complex m
Slide 5: Multi-Billion Dollar Portfolio
5 Multi - Billion Dollar Portfolio 1 . TAM - targeted addressable market 2 . ~ 90 % of eligible patients require eschar removal; assumes NexoBrid average price of ~$ 9,000 per patient 3 . Investigational drug 4 . Venous Leg Ulcers 5 . Diabetic Foot Ulcers 6 . Primary Research, Alira Health analysis
Slide 6: Product Pipeline
6 Product Pipeline 1 . U.S. Department of Defense 2 . Proof of Concept 3 . European Innovation Council Development Phase 1 Phase 2 Phase 3 Registration Marketed Indication Adult burn eschar removal Pediatric burn eschar removal Battlefield burn eschar removal Blast injury treatment VLU debridement D
Slide 7: 2024 Value Creating Milestones
NexoBrid ® 2024 7 Value Creating Milestones U.S. launch Phase 2 positive results Strategic collaborations FDA pediatric extension Battlefield IND submission EscharEx ® NexoBrid capacity increase U.S. facility: BARDA - funded planning and design EU governmental collaborations Battlefield facility con
Slide 8: Financial Highlights
8 Financial Highlights $ 44 M in cash 1 No debt € 16.25 M funding from EIC BALANCE SHEET 2024 revenue of $ 20 M NexoBrid ® is profitable Scale - up will potentially increase gross margin ~ 65 % $ 115 M+ received from BARDA $ 15 M funded by DoD REVENUE Outstanding shares: 10.8 M Fully diluted: 14.8 M
Slide 9: Early, effective and selective non-surgical eschar removal for severe burns
Early, effective and selective non - surgical eschar removal for severe burns Validated & commercialized Approved in 40 + countries including US, EU, JP; 14,000 + patients treated to date ( 8.8 % concentration)
Slide 10: First Step in Burn Care - Eschar Removal
1 . Edmondson et al., 2018 ; Burns 2 . Gurfinkel et al., 2010 ; Can J Plast Surg 10 First Step in Burn Care - Eschar Removal Removal of non - viable tissue is critical for wound healing Loss of healthy tissue and blood Surgical removal of eschar is traumatic & non - selective 1,2 Prevents infection
Slide 11: Non-Surgical, Simple, Selective, Effective
Indication: Eschar removal of deep partial - thickness and/or full - thickness thermal burns Commercial availability : US (Vericel), Japan (Kaken), Europe (direct, and PMI), India (Mankind) Government support: $ 115 M+ received from BARDA & DoD Contracts 11 Non - Surgical, Simple, Selective, Effecti
Slide 12: Phase 3 Studies Demonstrate Superiority
1 . Shoham et al. 2023 ; Journal of Burn care & Research 2 . Pediatric Phase 3 (CIDS), EU Phase 3 , Expanded Access Protocol (NEXT) 3 . Shoham et al. 2023 ; IWJ 12 Phase 3 Studies Demonstrate Superiority 1 Consistent across various studies 2 and post - marketing data 3 Safe and well - tolerated Impr
Slide 13: Growth Supported by Facility Scale-Up
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 2024 2025 2026 2027 BARDA/DoD/Other Prouct 1 . Global demand exceeds current manufacturing capability 3 X 2 . Subject to regulatory approvals 3 . Variability driven by development services revenue 13 Growth Supported by Facility Scale - Up 1 2026 2025 2024
Slide 14: Next-Generation Enzymatic Debridement Candidate for Chronic Wounds
Superior to SOC - aims to set a new bar for efficacy $ 2.5 B TAM opportunity De - risked - validated technology and successful Phase 2 trials Next - Generation Enzymatic Debridement Candidate for Chronic Wounds ( 5 % concentration)
Slide 15: EscharEx Targets Lower Extremity Chronic Ulcers
Debridement is a critical first step towards healing in both VLU and DFU 15 EscharEx ® Targets Lower Extremity Chronic Ulcers 1 . Primary Research, Alira Health analysis ( 2025 ) VLU Venous Leg Ulcers Underlying pathology - C hronic venous insufficiency Affects - Lower leg or ankle Ulcer characteris
Slide 16: Chronic Ulcers: Current Debridement Treatments are Sub-Optimal
Modalities by efficacy and complexity Modalities by ulcer type (U.S.) 1 Efficacy Trained Specialist Untrained HCP/ Nurses Ultrasonic Biological Sharp Current Enzymatic Autolytic 1 . Primary Research, Alira Health analysis ( 2025 ) 16 Chronic Ulcers: Current Debridement Treatments are Sub - Optimal S
Slide 17: EscharEx Enzymatic Debridement within Days
Indication: Rapid debridement and promotion of healthy granulation tissue (WBP) in chronic and hard - to - heal wounds 1,2 Status : Investigational drug 17 Eschar Ex ® Enzymatic Debridement within Days ▪ Debrides chronic ulcers within 4 - 8 daily administrations ▪ Easy - to - use topical application
Slide 18: Robust and Consistent Results in Three Phase 2 Studies
1 . Shoham et al. 2024 ; LANCET ’ s eClinicalMedicine 2 . Snyder et al. 2023 ; Wounds Journal 3 . Shoham et al. 2021 ; Wound Rep Reg 18 Robust and Consistent Results in Three Phase 2 Studies SCREENING DAILY WEEKLY NON - SURGICAL SOC FOLLOWUP PharmEx 2 VLU, DFU EscharEx n= 12 MW - EX 01 3 VLU, DFU, T
Slide 19: ChronEx Phase 2 Study - Endpoints Significantly Met
63 % 30 % 13 % 1 . Shoham et al. 2024 ; LANCET ’ s eClinicalMedicine 2 . Snyder et al. 2023 ; Wounds Journal; Shoham et al. 2021 ; Wound Rep Reg 19 ChronEx Phase 2 Study 1 - Endpoints Significantly Met No safety issues observed; efficacy results consistent with previous Phase 2 studies 2 EscharEx is
Slide 20: ChronEx Phase 2 Study - Rapid Wound Bed Preparation Achieved
Time to WBP Incidence of WBP 1 . Shoham et al. 2024 ; LANCET ’ s eClinicalMedicine 2 . Hazard Ratio 20 ChronEx Phase 2 Study 1 - Rapid Wound Bed Preparation Achieved 50 % 25 % 10 % EscharEx N = 23 Gel Vehicle N = 11 NSSOC N = 3 Study suggests that faster wound bed preparation increases the probabili
Slide 21: PharmEx Phase 2 Study - Surpassing Traditional Debridement
1 . Snyder et al., 2023 ; Wounds Journal 2 . The PharmEx trial included VLU and DFU patients 21 PharmEx Phase 2 Study - Surpassing Traditional Debridement Reduction in wound size, biofilm and bacterial burden 2 35 % Wound size reduced by end of two - week follow - up 65 % Bioburden reduction by end
Slide 22: EscharEx Well-Positioned to Become Market Leader
1 . The comparison presented represent cross - trial comparison 2 . OW Primary Research 3 . Lantis JC and Gordon I., 2017 ; Wounds 4 . Patry et al., 2017 5 . Snyder et al., 2023 ; Wounds 6 . SOC in the Phase 2 trial included SANTYL ® 7 . Based on the data to date 8 . SANTYL ® PI 22 EscharEx ® Well -
Slide 23: EscharEx vs. SANTYL Head-to-Head Data
1 . Post - hoc data from the ChronEx Phase 2 study 2 . Comparable incidence of adverse wound reactions identified 23 EscharEx ® vs. SANTYL ® Head - to - Head Data 1 Consistent results in pediatric Phase 3 study, EU Phase 3 study and post marketing data 2 Patie nt - rep orted pain 2 Incidence of comp
Slide 24: EscharEx VALUE Phase 3 Study in VLU Patients
Safety: Safety & tolerability | ECG | Change in pain | Wound infection rates | Immunogenicity Research collaborations with Solventum , Mölnlycke and MIMEDX 24 EscharEx ® VALUE Phase 3 Study in VLU Patients STUDY OBJECTIVES To assess safety and efficacy of EscharEx compared to placebo in VLU patients
Slide 25: EscharEx Planned Phase 2/3 Study in DFU Patients
Safety: Safety & tolerability | ECG | Change in pain | Wound infection rates | Immunogenicity € 16.25 M funding from the European Innovation Council accelerator 25 EscharEx ® Planned Phase 2 / 3 Study in DFU Patients STUDY OBJECTIVES 1 To assess safety and efficacy of EscharEx compared to placebo in
Slide 26: Primary Research Shows EscharEx Transforms Market
EscharEx draws share across all debridement modalities 6 18 % 30 % EscharEx SANTYL 1 . Alira Health analysis ( 2025 ) 2 . Qualitative (N= 21 ), quantitative (N= 96 ) across all care settings, HCPs and payors 3 . Skilled Nursing Facilities/Long - Term Care 4 . Home Health Agencies 5 . Wound Care Cent
Slide 27: $725M Projected Peak Sales in $2.5B TAM in U.S.
1 . Primary research, Alira Health analysis ( 2025 ). 2 . Secondary research . 3 . Peak projected revenues occur at 5 Y/ 4 Y post launch of VLU/DFU, respectively 27 $ 725 M Projected Peak Sales in $ 2.5 B TAM in U.S. 1 DFU & VLU d ebridement patients Percent of patients undergoing debridement quanti
Slide 28: Highly Experienced Leadership Team
28 Highly Experienced Leadership Team Ofer Gonen CEO Dr. Ety Klinger Chief R&D Officer Nachum (Homi) Shamir Chairman Dr. Robert J. Snyder CMO Barry Wolfenson EVP Strategy & Corp Dev. Hani Luxenburg CFO Dr. Shmulik Hess COO & CCO
Slide 29: Strategic Timeline
NexoBrid U.S. launch 29 Strategic Timeline 2027 - 8 2024 2025 2026 EscharEx VLU Phase Interim assessment; Last patient out $ 25 M PIPE + € 16.25 M EIC funding EscharEx VLU Phase execution NexoBrid $ 24 - 26 M revenue EscharEx vs. collagenase Head - to - Head study EscharEx FDA approval $ 75 M+ reven